Expert Opinion on Investigational Drugs, Volume 19, Issue 2 (2010)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 19, Issue 2 (2010)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Volume 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Original Research

Article
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release
Håkon Reikvam, Kimberley Joanne Hatfield, Philippe Lassalle, Astrid Olsnes Kittang, Elisabeth Ersvær & Øystein Bruserud
Pages: 169-183
Published online: 05 Jan 2010
AbstractforTargeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release | Full Text | References | PDF (812.4 KB)
  • 343 Views
  • 35 CrossRef citations
  • 0Altmetric

Reviews

Article
Ketoconazole enantiomer for the treatment of diabetes mellitus
Richard Arakaki MD & Bernice Welles MD MBA
Pages: 185-194
Published online: 05 Jan 2010
AbstractforKetoconazole enantiomer for the treatment of diabetes mellitus | Full Text | References | PDF (320.6 KB)
  • 245 Views
  • 17 CrossRef citations
  • 0Altmetric
Article
Clinically validated approaches to the treatment of autoimmune diseases
Percy H Carter PhD & Qihong Zhao MD PhD
Pages: 195-213
Published online: 06 Jan 2010
AbstractforClinically validated approaches to the treatment of autoimmune diseases | Full Text | References | PDF (674.8 KB)
  • 265 Views
  • 24 CrossRef citations
  • 0Altmetric
Article
Newer antibacterial drugs for a new century
Gina Devasahayam PhD, William M Scheld PhD & Paul S Hoffman PhD
Pages: 215-234
Published online: 07 Jan 2010
AbstractforNewer antibacterial drugs for a new century | Full Text | References | PDF (654.3 KB)
  • 645 Views
  • 103 CrossRef citations
  • 0Altmetric
Article
A new target for proteasome inhibitors: FoxM1
Andrei L Gartel
Pages: 235-242
Published online: 15 Jan 2010
AbstractforA new target for proteasome inhibitors: FoxM1 | Full Text | References | PDF (649.5 KB)
  • 481 Views
  • 69 CrossRef citations
  • 0Altmetric
Article
Targeting silibinin in the antiproliferative pathway
Lei Li PhD, Jin Zeng PhD, Ye Gao PhD & Dalin He MD
Pages: 243-255
Published online: 05 Jan 2010
AbstractforTargeting silibinin in the antiproliferative pathway | Full Text | References | PDF (972.3 KB)
  • 283 Views
  • 53 CrossRef citations
  • 0Altmetric
Article
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Guy F Joos
Pages: 257-264
Published online: 05 Jan 2010
AbstractforPotential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease | Full Text | References | PDF (570.6 KB)
  • 470 Views
  • 21 CrossRef citations
  • 0Altmetric
Article
Targeted therapy of hepatocellular cancer
Piotr Jan Wysocki MD PhD
Pages: 265-274
Published online: 15 Jan 2010
AbstractforTargeted therapy of hepatocellular cancer | Full Text | References | PDF (578.9 KB)
  • 489 Views
  • 47 CrossRef citations
  • 0Altmetric

Drug Evaluations

Article
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease
Monique E Cho & Jeffrey B Kopp
Pages: 275-283
Published online: 06 Jan 2010
AbstractforPirfenidone: an anti-fibrotic therapy for progressive kidney disease | Full Text | References | PDF (597.7 KB)
  • 539 Views
  • 78 CrossRef citations
  • 0Altmetric
Article
Tagatose: from a sweetener to a new diabetic medication?
Ikna Espinosa DO & Leon Fogelfeld MD
Pages: 285-294
Published online: 06 Jan 2010
AbstractforTagatose: from a sweetener to a new diabetic medication? | Full Text | References | PDF (654.3 KB)
  • 486 Views
  • 44 CrossRef citations
  • 0Altmetric
Article
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
Michelle Head MB ChB & Michael B Jameson FRACP FRCP(Edin) PhD
Pages: 295-304
Published online: 06 Jan 2010
AbstractforThe development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities | Full Text | References | PDF (600.9 KB)
  • 296 Views
  • 33 CrossRef citations
  • 0Altmetric
Article
NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia
Neal Shore MD FACS
Pages: 305-310
Published online: 05 Jan 2010
AbstractforNX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia | Full Text | References | PDF (1.4 MB)
  • 422 Views
  • 33 CrossRef citations
  • 0Altmetric

Key Paper Evaluation

Article
Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects
Evaluation of: Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009;69:4309-18
Emmanuel S Antonarakis & Michael A Carducci
Pages: 311-314
Published online: 05 Jan 2010
AbstractforCombining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects | Full Text | References | PDF (535.6 KB)
  • 136 Views
  • 11 CrossRef citations
  • 0Altmetric

Explore articles